BiondVax Pharmaceuticals Ltd. (BVXV), an Israeli-based clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, announced that their patent application on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines was accepted in Israel.
Dedicated to the development of a universal flu vaccine, BiondVax’s technology utilizes a unique, proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd. for developing, manufacturing and commercializing the vaccine.
"We are very pleased that the Israeli patent authorities accepted the uniqueness of our universal flu vaccine solution, approving this main patent of BiondVax,” said Ron Babecoff, CEO of BiondVax. “Our solution is patent protected in many of the countries where we believe our vaccine will provide increased protection to the local population from flu, including multiple European countries, in the United States and in the Far East."
BiondVax also holds patent protection in various countries, namely the United States, Europe, Japan, Hong Kong, Australia, China, Russia, and Mexico. In November, the company received patent approval in Korea as well.Furthermore, the company recently revealed significant progress in their third quarter of 2015 towards an interim goal of reaching phase 3 trials in the 2017/2018.
The flu leaves millions around the world vulnerable, particularly children and the elderly, to other life-threatening infections. Not only does BiondVax’s Universal Flu Vaccine protect against all flus, the vaccine will also provide a much needed relief to fighting a pandemic threat. With Israel added to the growing list of countries where this technology is approved, BiondVax is bringing the world one step closer to a solution that actually works.
For more information about BiondVax, visit www.biondvax.com.
Disclosure: In the purview of Section
17(B) of the Securities Act of 1933 and in the interest of full
disclosure, we call the reader's attention the fact that
Equities.com, Inc. may be compensated by the companies profiled in
the Spotlight Companies section. The purpose of these profiles is to
provide awareness of these companies to investors in the micro,
small-cap and growth equity community and should not in any way come
across as a recommendation to buy, sell or hold these securities.
Equities.com is not a registered broker, broker dealer, investment
advisor, analyst, investment banker or underwriter. All profiles are
based on information that is available to the public. The information
contained herein should not be considered to be all-inclusive and is
not guaranteed by Equities.com to be free from misstatement or
errors. Readers are reminded to do their own due diligence when
researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer